| Literature DB >> 17040626 |
Katherine Stemke-Hale1, Bryan Hennessy, Gordon B Mills, Rahul Mitra.
Abstract
The completion of the human genome project, along with the ancillary technologies derived from this effort, provides the ability to comprehensively analyze patient tumors as well as the individual patient's own genetic make-up at the DNA, RNA, and protein level. As a result, novel molecular screening techniques have the potential to push the boundaries of detection to even smaller tumors and also to allow accurate risk assessment, cancer prevention, and treatment planning in individual women. This review focuses on advances over the past 2 years in the use of molecular signatures and circulating tumor cells for early breast cancer detection and for prediction of response to therapy.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17040626 DOI: 10.1007/s11912-006-0078-5
Source DB: PubMed Journal: Curr Oncol Rep ISSN: 1523-3790 Impact factor: 5.075